Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X

Find the latest Drugs in Development and Pipeline Prospector News of Sparian Biosciences.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Sparian Biosciences
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
180 Varick Street, New York, New York 10014-0121
Telephone
Telephone
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The net proceeds will be used to fund development of SBS-518, a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder, from IND submission through Phase 1 clinical development.


Lead Product(s): SBS-518

Therapeutic Area: Psychiatry/Psychology Product Name: SBS-518

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $19.0 million Upfront Cash: Undisclosed

Deal Type: Funding August 08, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY